Tuesday, December 12, 2006

Utah Technology Spinoff Gets Funds

Houston, Texas-based ThromboVision, a developer of biomedical diagnostics products based on technology from the Utah Artificial Heart Research Institute, Brigham Young University, and the University of Utah, has raised $400K in the first tranche of a Series A financing. The firm said that the investment will be used to fund the firm's clinical trials, to build its infrastructure, and advanced FDA approval. ThromboVision is developing a system to monitor platelet function. The firm includes founders from the Utah Artificial Heart Research Institute, BYU and the University of Utah.